Abstract
Nicotinamide is the primary precursor of nicotinamide adenine dinucleotide (NAD) [1], which is required for the manufacture of adenosine triphosphate (ATP) in the citric acid cycle (Fig. 11.1). Ultraviolet (UV) irradiation causes both DNA damage and depletion of cellular energy (NAD) [2], which is required for efficient DNA repair. Following UV irradiation, cellular NAD content is an important determinant of cell survival [2]. Human skin cells with reduced levels of NAD have a lower survival rate and higher genomic instability following UV exposure [2], whereas increased intracellular NAD is associated with enhanced protection against photo-oxidative stress [3]. As the precursor of NAD, nicotinamide would be expected to enhance DNA repair in UV-irradiated cells. At low concentrations (less than 3 mM), nicotinamide does enhance repair in UV-irradiated, repair-proficient cell lines, although with higher nicotinamide concentrations (5 mM), DNA repair returned to control levels [4].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jacobson, E.L., Dame, A.J., Pyrek, J.S., et al.: Evaluating the role of niacin in human carcinogenesis. Biochimie 77, 394–398 (1995)
Jacobson, E.L., Giacomoni, P.U., Roberts, M.J., et al.: Optimizing the energy status of skin cells during solar radiation. J. Photochem. Photobiol. B Biol. 63, 141–147 (2001)
Wright, S.C., Wei, Q.S., Kinder, D.H., et al.: Biochemical pathways of apoptosis: nicotinamide adenine dinucleotide-deficient cells are resistant to tumor necrosis factor or ultraviolet light activation of the 24-kD apoptotic protease and DNA fragmentation. J. Exp. Med. 183, 463–471 (1996)
Riklis, E., Kor, R., Marko, R.: Trends and developments in radioprotection: the effect of nicotinamide on DNA repair. Int. J. Radiat. Biol. 57, 699–708 (1990)
Berger, N.A.: Poly(ADP-ribose) in the cellular response to DNA damage. Radiat. Res. 101, 4–15 (1985)
de Murcia, J.M., Niedergang, C., Trucco, C., et al.: Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. USA 94, 7303–7307 (1997)
Chatterjee, S., Cheng, M.F., Berger, N.A.: Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines. Cancer Commun. 2, 401–407 (1990)
Virag, L., Szabo, C.: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54, 375–429 (2002)
Kripke, M.L., Cox, P.A., Alas, L.G., et al.: Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice. Proc. Natl. Acad. Sci. USA 89, 7516–7520 (1992)
Ying, W., Garnier, P., Swanson, R.A.: NAD+ repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 308, 809–813 (2003)
Cosmetic Ingredient Review (CIR) Expert Panel. Final report of the safety assessment of niacinamide and niacin. Int. J. Toxicol. 24(Suppl 5), 1–31 (2005)
Drugdex drug evaluations: niacinamide. In: Klasco, R. (ed.) DrugDex(R) System. Thomsom Micromedex, Greenwood Village, Colorado (2006)
Magni, G., Amici, A., Emanuelli, M., et al.: Enzymology of NAD+ homeostasis in man. Cell. Mol. Life Sci. 61, 19–34 (2004)
Morris, M.C., Evans, D.A., Bienias, J.L., et al.: Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline. J. Neurol. Neurosurg. Psychiatry 75, 1093–1099 (2004)
Karthikeyan, K., Thappa, D.M.: Pellagra and skin. Int. J. Dermatol. 41, 476–481 (2002)
Hegyi, J., Schwartz, R.A., Hegyi, V.: Pellagra: dermatitis, dementia, and diarrhea. Int. J. Dermatol. 43, 1–5 (2004)
Murray, M.F.: Tryptophan depletion and HIV infection: a metabolic link to pathogenesis. Lancet Infect. Dis. 3, 644–652 (2003)
Bilu, D., Mamelak, A.J., Nguyen, R.H., et al.: Clinical and epidemiologic characterization of photosensitivity in HIV-positive individuals. Photodermatol. Photoimmunol. Photomed. 20, 175–183 (2004)
DiPalma, J.R., Thayer, W.S.: Use of niacin as a drug. Annu. Rev. Nutr. 11, 169–187 (1991)
Petley, A., Macklin, B., Renwick, A.G., et al.: The pharmacokinetics of nicotinamide in humans and rodents. Diabetes 44, 152–155 (1995)
Hoskin, P.J., Stratford, M.R., Saunders, M.I., et al.: Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity. Int. J. Radiat. Oncol. Biol. Phys. 32, 1111–1119 (1995)
Dragovic, J., Kim, S.H., Brown, S.L., et al.: Nicotinamide pharmacokinetics in patients. Radiother. Oncol. 36, 225–228 (1995)
Stratford, M.R., Rojas, A., Hall, D.W., et al.: Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother. Oncol. 25, 37–42 (1992)
Kaanders, J.H., Stratford, M.R., Liefers, J., et al.: Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance. Radiother. Oncol. 43, 67–73 (1997)
Yiasemides, E., Sivapirabu, G., Halliday, G.M., et al.: Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis 30, 101–105 (2009)
Knip, M., Douek, I.F., Moore, W.P., et al.: Safety of high-dose nicotinamide: a review. Diabetologia 43, 1337–1345 (2000)
Horsman, M.R., Hoyer, M., Honess, D.J., et al.: Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother. Oncol. 27, 131–139 (1993)
Neumann, R., Rappold, E., Pohl-Markl, H.: Treatment of polymorphous light eruption with nicotinamide: a pilot study. Br. J. Dermatol. 115, 77–80 (1986)
Chaffins, M.L., Collison, D., Fivenson, D.P.: Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J. Am. Acad. Dermatol. 28, 998–1000 (1993)
Bernier, J., Stratford, M.R., Denekamp, J., et al.: Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Radiother. Oncol. 48, 123–133 (1998)
Kademian, M., Bechtel, M., Zirwas, M.: Case reports: new onset flushing due to unauthorized substitution of niacin for nicotinamide. J. Drugs Dermatol. 6, 1220–1221 (2007)
Kolbach, D.N., Remme, J.J., Bos, W.H., et al.: Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br. J. Dermatol. 133, 88–90 (1995)
Fivenson, D.P., Breneman, D.L., Rosen, G.B., et al.: Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch. Dermatol. 130, 753–758 (1994)
Gaudineau, C., Auclair, K.: Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem. Biophys. Res. Commun. 317, 950–956 (2004)
COLIPA: COLIPA sun protection factor test method. Report No.: 94/289, The European Cosmetic Toiletry and Perfumery Association, Brussells (1994)
Reiche, L., Wojnarowska, F., Mallon, E.: Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin. Exp. Dermatol. 23, 254–257 (1998)
Fivenson, D.P., Kimbrough, T.L.: Lichen planus pemphigoides: combination therapy with tetracycline and nicotinamide. J. Am. Acad. Dermatol. 36, 638–640 (1997)
Berk, M.A., Lorincz, A.L.: The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch. Dermatol. 122, 670–674 (1986)
Goon, A.T., Tan, S.H., Khoo, L.S., et al.: Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore. Singapore Med. J. 41, 327–330 (2000)
Chaidemenos, G.C.: Tetracycline and niacinamide in the treatment of blistering skin diseases. Clin. Dermatol. 19, 781–785 (2001)
Burger, D.R., Vandenbark, A.A., Daves, D., et al.: Nicotinamide: suppression of lymphocyte transformation with a component identified in human transfer factor. J. Immunol. 117, 797–801 (1976)
Handfield-Jones, S., Jones, S., Peachey, R.: High dose nicotinamide in the treatment of necrobiosis lipoidica. Br. J. Dermatol. 118, 693–696 (1988)
Shalita, A.R., Smith, J.G., Parish, L.C., et al.: Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int. J. Dermatol. 34, 434–437 (1995)
Draelos, Z.D., Ertel, K., Berge, C.: Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis 76, 135–141 (2005)
Hakozaki, T., Minwalla, L., Zhuang, J., et al.: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br. J. Dermatol. 147, 20–31 (2002)
Tanno, O., Ota, Y., Kitamura, N., et al.: Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br. J. Dermatol. 143, 524–531 (2000)
Soma, Y., Kashima, M., Imaizumi, A., et al.: Moisturizing effects of topical nicotinamide on atopic dry skin. Int. J. Dermatol. 44, 197–202 (2005)
Halliday, G.M., Rana, S.: The effects of solar radiation on the immune response in humans. In: Giacomoni, P.U. (ed.) Biophysical and Physiological Effects of Solar Radiation on Human Skin. The Royal Society for Chemistry, Cambridge pp. 127–163 (2007)
Halliday, G.M.: Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat. Res. 571, 107–120 (2005)
Kuchel, J.M., Barnetson, R.S., Halliday, G.M.: Nitric oxide appears to be a mediator of solar-simulated ultraviolet radiation-induced immunosuppression in humans. J. Invest. Dermatol. 121, 587–593 (2003)
Yuen, K.S., Nearn, M.R., Halliday, G.M.: Nitric oxide-mediated depletion of Langerhans cells from the epidermis may be involved in UVA radiation-induced immunosuppression. Nitric Oxide 6, 313–318 (2002)
Hornig-Do, H.T., von Kleist-Retzow, J.C., KLanz, K., et al.: Human epidermal keratinocytes accumulate superoxide due to low activity of Mn-SOD, leading to mitochondrial functional impairment. J. Invest. Dermatol. 127, 1084–1093 (2007)
Kuchel, J.M., Barnetson, R.S.C., Halliday, G.M.: Cyclobutane pyrimidine dimer formation is a molecular trigger for solar-simulated ultraviolet radiation-induced suppression of memory immunity in humans. Photochem. Photobiol. Sci. 4, 577–582 (2005)
Halliday, G.M.B., Bock, V.L., Moloney, F.J., Lyons, J.G.: SWI/SNF: a chromatin-remodelling complex with a role in carcinogenesis. Int. J. Biochem. Cell. Biol. 41, 725–728
Fousteri, M., Mullenders, L.H.: Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects. Cell Res. 18, 73–84 (2008)
Byrne, S.N., Halliday, G.M.: B cells activated in lymph nodes in response to ultraviolet irradiation or by interleukin-10 inhibit dendritic cell induction of immunity. J. Invest. Dermatol. 124, 570–578 (2005)
Rana, S., Byrne, S.N., MacDonald, L.J., et al.: Ultraviolet B suppresses immunity by inhibiting effector and memory T cells. Am. J. Pathol. 172, 993–1004 (2008)
Gensler, H.L.: Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide. Nutr. Cancer 29, 157–162 (1997)
Gensler, H.L., Williams, T., Huang, A.C., et al.: Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr. Cancer 34, 36–41 (1999)
Ludwig, A., Dietel, M., Schafer, G., et al.: Nicotinamide and nicotinamide analogues as antitumor promoters in mouse skin. Cancer Res. 50, 2470–2475 (1990)
Damian, D.L., Halliday, G.M.: Measurement of ultraviolet radiation-induced suppression of recall contact and delayed-type hypersensitivity in humans. Methods 28, 34–45 (2002)
Phan, T.A., Halliday, G.M., Barnetson, R.S., et al.: Spectral and dose dependence of ultraviolet radiation-induced immunosuppression. Front. Biosci. 11, 394–411 (2006)
Halliday, G.M., Bestak, R., Yuen, K.S., et al.: UVA-induced immunosuppression. Mutat. Res. 422, 139–145 (1998)
Damian, D.L., Barnetson, R.S., Halliday, G.M.: Low-dose UVA and UVB have different time courses for suppression of contact hypersensitivity to a recall antigen in humans. J. Invest. Dermatol. 112, 939–944 (1999)
Wolf, P., Hoffmenn, C., Quehenberger, F., et al.: Immune protection factors of chemical sunscreens measured in the local contact hypersensitivity model in humans. J. Invest. Dermatol. 121, 1080–1087 (2003)
Damian, D.L., Barnetson, R.S., Halliday, G.M.: Effects of low-dose ultraviolet radiation on in vivo human cutaneous recall responses. Australas. J. Dermatol. 42, 161–167 (2001)
Gensler, H.L., Williams, T., Huang, A.C., et al.: Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr. Cancer 34, 36–41 (1999)
Gensler, H.L.: Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide. Nutr. Cancer 29, 157–162 (1997)
Damian, D.L., Patterson, C.R.S., Stapelberg, M., et al.: Ultraviolet radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J. Invest. Dermatol. 128, 447–454 (2008)
Bouros, D., Zeros, G., Panaretos, C., et al.: Palpation vs pen method for the measurement of skin tuberculin reaction (Mantoux test). Chest 99, 416–419 (1991)
Damian, D.L., Halliday, G.M., Taylor, C.A., et al.: Ultraviolet radiation induced suppression of Mantoux reactions in humans. J. Invest. Dermatol. 110, 824–827 (1998)
Sivapirabu, G., Yiasemides, E., Halliday, G.M., Park, J., Damian, D.L.: Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. British Journal of Dermatology 161, 1357–1364 (2009)
Bissett, D.L., Oblong, J.E., Berge, C.A.: Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatol. Surg. 31, 860–865 (2005)
Kawada, A., Konishi, N., Oiso, N., et al.: Evaluation of anti-wrinkle effects of a novel cosmetic containing niacinamide. J. Dermatol. 35, 637–642 (2008)
Hazozaki, T., Minwalla, L., Zhuang, J., et al.: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br. J. Dermatol. 147, 20–31 (2002)
Ungerstedt, J.S., Blomback, M., Soderstrom, T.: Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin. Exp. Immunol. 131, 48–52 (2003)
Hedman, M., Ludvigsson, J., Faresjo, M.K.: Nicotinamide reduces high secretion of IFN-gamma in high-risk relatives even though it does not prevent type 1 diabetes. J. Interferon Cytokine Res. 26, 207–213 (2006)
Bogan, K.L., Brenner, C.: Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. Nutr. 28, 115–130 (2008)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Damian, D.L., Halliday, G.M. (2010). Photoprotection by Nicotinamide. In: Krutmann, J., Humbert, P. (eds) Nutrition for Healthy Skin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12264-4_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-12264-4_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12263-7
Online ISBN: 978-3-642-12264-4
eBook Packages: MedicineMedicine (R0)